Together, our results demonstrate that the delivery of anti-IFNγ antibody to the capillary site by CREKA-lipo-anti-IFNγ may be beneficial for cancer patients undergoing chemotherapy, which can be explored as a new strategy for the treatment of lung cancer. Here, IFNG is linked to lung cancer.